Aspira Women’s Health Inc. (AWH) is actively engaged in the development and marketing of novel bio testing solutions and analysis options to improve women’s gynecologic health-related products. The company is involved in product development for detecting ovarian cancers, endometriosis, and pelvic diseases. The lead products of the company include OVA1 and OVERA, used in detecting ovarian malignancy risk. GenetiX detects comprehensive and targeted genetic testing options with the main focus on gynecology.
The price of AWP stock during the regular trading on January 31, 2022, was $1.21 with a sharp increase of 12.04%. At last check in the aftermarket, the stock further rocketed by 27.2%.
AWH: Events and Happenings
On January 31, 2022, AWH reported about its entry into a collaborative agreement to offer its testing services to Medicaid plan members equaling up to 465,000 covered lives in New Hampshire and Washington D.C. Thus, the company is credentialed as OVA1 testing provider to approximately 80% or 60 million lives of the Medicaid population.
AWH: CEO Comments
Speaking at the occasion, AWH CEO Valerie Palmieri said that this agreement steadfast the company’s pledge to guarantee equal access to the Medicaid population for its non-invasive ovarian cancer risk management technology.
On January 28, 2022, AWH’s management was reported to present at The Virtual Winter Wonderland Best Ideas Investor Conference which will be held on February 8-11, 2022. On January 05, 2022, AWH reported about its entry into a commercial contract with Axia Women’s Health. Axia will provide the services to conduct in-house genetic testing using the exclusive Aspira Synergy Genetics portfolio. The term of the contract is five years.
On January 05, 2022, AWH reported initial Q4 2021 operational results. Some of the highlights are as follows.
- OVA1 volume in Q4 2021 increased to 4,750 units by a 23.4% incline over the year.
- Ordering physicians number surged by 22.8% over the year to 3,211 in Q4 2021.
AWH: Key Financials
On November 10, 2021, AWH announced its financial results for the third quarter ended September 30, 2021. Some of the key features are as follows.
Revenue
Total revenue in Q3 2021 was $1.66 million compared to $1.23 in the same quarter of 2020, an increase of 34% was observed over the year.
Net Loss per Share
Basic and diluted net loss per share in Q3 2021 was $9.7 million or $0.09 compared to $4.2 million or $0.04 in the same period in 2020.
Conclusion
AWH stock dipped 73% in the last six months period due to the impact of the pandemic on the economy. The rocketing stock price in the current aftermarket is the result of the latest agreement to provide the testing services to Medicaid plan members. The financial experts predicted that with the current developmental speed, the company may achieve new heights in the women’s health industry.
